SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0003

Change

0.00 (0.00)%

Market Cap

USD 0.01M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

+0.45 (+0.51%)

USD 34.50B
UCBJF UCB SA

N/A

USD 34.08B
ARGNF argenx SE

N/A

USD 32.00B
GNMSF Genmab A/S

-4.58 (-1.72%)

USD 17.00B
ZLDPF Zealand Pharma A/S

N/A

USD 9.86B
IVBIY IVBIY

N/A

USD 8.92B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.29B
AKESF Akeso, Inc.

-0.52 (-5.78%)

USD 7.07B
WXIBF WuXi Biologics

N/A

USD 6.08B
WXXWY WuXi Biologics (Cayman) Inc

+0.18 (+6.21%)

USD 6.08B

ETFs Containing SCPS

IEO 19.45 % 0.42 %

N/A

N/A
WTID UBS ETRACS - ProShares Da.. 11.60 % 0.00 %

-0.68 (2.06%)

USD 5.15M
WTIU UBS ETRACS - ProShares Da.. 11.60 % 0.00 %

+0.51 (+2.06%)

USD 8.63M
IS0D:F iShares Oil & Gas Explora.. 10.25 % 0.00 %

+0.36 (+2.06%)

N/A
IS0D:XETRA iShares Oil & Gas Explora.. 10.25 % 0.00 %

+0.42 (+2.06%)

USD 0.32B
IOGP:LSE iShares Oil & Gas Explora.. 10.18 % 0.00 %

+0.55 (+2.06%)

N/A
SPOG:LSE iShares V Public Limited .. 10.18 % 0.00 %

+30.75 (+2.06%)

N/A
NRGD MicroSectors U.S. Big Oil.. 10.00 % 0.00 %

N/A

USD 0.08B
NRGU MicroSectors U.S. Big Oil.. 10.00 % 0.00 %

N/A

N/A
NRGO 10.00 % 0.00 %

N/A

N/A
NRGZ 10.00 % 0.00 %

N/A

N/A
YGRN 10.00 % 0.00 %

N/A

N/A
FRAK 8.73 % 0.54 %

N/A

N/A
IUES:LSE iShares S&P 500 Energy Se.. 7.86 % 0.00 %

+0.16 (+2.06%)

USD 0.84B
IUSE:LSE iShares S&P 500 EUR Hedge.. 7.86 % 0.00 %

+1.74 (+2.06%)

USD 5.97B
QDVF:F iShares S&P 500 Energy Se.. 7.86 % 0.00 %

N/A

N/A
QDVF:XETRA iShares S&P 500 Energy Se.. 7.86 % 0.00 %

+0.14 (+2.06%)

USD 0.98B
FTXN First Trust Nasdaq Oil & .. 7.79 % 0.60 %

+0.33 (+2.06%)

USD 0.17B
IESU:LSE iShares S&P 500 Energy Se.. 7.71 % 0.00 %

+9.38 (+2.06%)

N/A
XUEN:F Xtrackers (IE) Public Lim.. 7.59 % 0.00 %

+0.63 (+2.06%)

USD 0.09B
XUEN:XETRA db x-trackers MSCI USA En.. 7.59 % 0.00 %

+0.70 (+2.06%)

USD 0.09B
XSEN:LSE db x-trackers MSCI USA En.. 7.40 % 0.00 %

+46.00 (+2.06%)

USD 0.07B
XUEN:LSE db x-trackers MSCI USA En.. 7.40 % 0.00 %

+0.84 (+2.06%)

USD 0.07B
IYE iShares U.S. Energy ETF 7.17 % 0.42 %

+0.54 (+2.06%)

N/A
JHME 6.90 % 0.48 %

N/A

N/A
NXF-B:CA CI Energy Giants Covered .. 6.66 % 0.00 %

+0.12 (+2.06%)

CAD 0.02B
FENY Fidelity® MSCI Energy In.. 6.60 % 0.08 %

+0.31 (+2.06%)

USD 1.57B
DDG 5.83 % 0.95 %

N/A

N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

-0.24 (2.06%)

N/A
HPF-U:CA Harvest Energy Leaders Pl.. 4.96 % 0.00 %

N/A

N/A
ERYY 4.79 % 0.45 %

N/A

N/A
FILL iShares MSCI Global Energ.. 4.73 % 0.39 %

+0.38 (+2.06%)

USD 0.10B
WNRG:LSE SPDR MSCI World Energy UC.. 4.71 % 0.00 %

+0.89 (+2.06%)

N/A
XDW0:LSE db x-trackers MSCI World .. 4.70 % 0.00 %

+0.94 (+2.06%)

N/A
XDW0:F Xtrackers (IE) Public Lim.. 4.70 % 0.00 %

N/A

USD 1.07B
XDW0:XETRA db x-trackers MSCI World .. 4.70 % 0.00 %

+0.74 (+2.06%)

USD 1.07B
5MVW:XETRA iShares MSCI World Energy.. 4.60 % 0.00 %

+0.13 (+2.06%)

USD 0.59B
FCG First Trust Natural Gas E.. 4.52 % 0.60 %

+0.27 (+2.06%)

N/A
ZPDE:F SPDR S&P U.S. Energy Sele.. 4.49 % 0.00 %

+0.47 (+2.06%)

USD 0.78B
ZPDE:XETRA SPDR® S&P® U.S. Energy .. 4.49 % 0.00 %

+0.50 (+2.06%)

USD 0.78B
HUL-U:CA 4.46 % 0.00 %

N/A

N/A
HUL:CA 4.46 % 2.20 %

N/A

N/A
SXLE:LSE SPDR S&P U.S. Energy Sele.. 4.46 % 0.00 %

+0.67 (+2.06%)

N/A
IXC iShares Global Energy ETF 4.42 % 0.46 %

+0.46 (+2.06%)

N/A
IGE 4.31 % 0.46 %

N/A

N/A
NANR SPDR S&P® North American.. 4.30 % 0.35 %

+0.97 (+2.06%)

N/A
GASX 4.29 % 1.01 %

N/A

N/A
DIG ProShares Ultra Oil & Gas 3.48 % 0.95 %

+0.84 (+2.06%)

N/A
ERX Direxion Daily Energy Bul.. 3.12 % 1.08 %

+1.35 (+2.06%)

N/A
XOP SPDR® S&P Oil & Gas Expl.. 3.03 % 0.35 %

+2.15 (+2.06%)

N/A
HEA:CA 2.61 % 0.00 %

N/A

N/A
HEA-U:CA 2.61 % 0.00 %

N/A

N/A
FCUQ:CA Fidelity U.S. High Qualit.. 2.19 % 0.00 %

+0.65 (+2.06%)

CAD 0.61B
SPGP Invesco S&P 500 GARP ETF 1.96 % 0.36 %

+2.00 (+2.06%)

USD 4.33B
GUSH Direxion Daily S&P Oil & .. 1.88 % 1.04 %

+0.88 (+2.06%)

USD 0.32B
GASL 1.45 % 1.19 %

N/A

N/A
TERM 0.88 % 0.64 %

N/A

N/A
RIRA:CA Russell Investments Real .. 0.60 % 0.00 %

-0.04 (2.06%)

CAD 0.21B
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

+0.05 (+2.06%)

N/A
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

-0.13 (2.06%)

N/A
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

+0.09 (+2.06%)

N/A
ILF iShares Latin America 40 .. 0.00 % 0.48 %

+0.16 (+2.06%)

N/A
MTUM 0.00 % 0.15 %

N/A

N/A
RYE 0.00 % 0.40 %

N/A

N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

+0.10 (+2.06%)

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

+6.89 (+2.06%)

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

+4.50 (+2.06%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.30% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.30% 4% F 1% F
Trailing 12 Months  
Capital Gain -99.39% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.39% 4% F 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -66.11% 1% F N/A F
Dividend Return -66.11% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.64% 73% C 59% D-
Risk Adjusted Return -162.66% 2% F N/A F
Market Capitalization 0.01M 9% A- 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.